Molecular and Cellular Biochemistry

, Volume 156, Issue 2, pp 135–143 | Cite as

Subchronic exposure of cardiomyocytes to low concentrations of tumor necrosis factor α attenuates the positive inotropic response not only to catecholamines but also to cardiac glycosides and high calcium concentrations

  • Peter Boekstegers
  • Iris Kainz
  • Wolfgang Giehrl
  • Wolfgang Peter
  • Karl Werdan
Article

Abstract

The main purpose of this study was to determine the subchronic effects of low concentrations of tumor necrosis factor α (TNFα) on the inotropic response and on the cellular level of high energy phosphates of cardiomyocytes. Therefore, the inotropic response of cultured neonatal rat heart cells to 10−5 M isoproterenol-, 10−6 M ouabain-, 10−5 M forskolin- and 2,4 mM calcium-perfusion was studied 24 h after exposure to TNFα (0.01/0.1/1/10/100 U/ml). In parallel experiments high energy phosphates (CP, ATP, ADP, AMP) were determined by high performance liquid chromatography. Furthermore, the reversibility of TNFα-induced changes was studied after washout of TNFα or after administration of anti-TNFα-antibody. Whereas control cells showed an increase of cell wall motion to 150 ± 5% of baseline value during 10-5 M isoproterenol-perfusion respectively 180 ± 7% during 2,4 mM calcium-perfusion, 24 h exposure of the cells to 1 U/ml up to 100 U/ml TNFα resulted in an inhibition of the inotropic response. Almost complete inhibition was observed 12 h after exposure to TNFα and was reversible 12 h after administration of the anti-TNFa-antibody. If the cells were perfused with 10−6 M ouabain or 10−5 M forskolin, a similar inhibition of the inotropic response was observed 24 h after TNFα-exposure. Determination of high energy phosphates showed that 24 h TNFα-exposure resulted in a reversible decrease of ATP, ADP, AMP and CP by 30–40% (p < 0.05). However, a similar reduction of cellular high energy phosphate levels using a TNFα independent mechanism (2,5 mM 2-deoxy-D-glucose) did not inhibit the inotropic response of the cardiomyocytes. From our results we conclude that subchronic exposure to low concentrations of TNFα resulted in an almost complete but reversible inhibition of the response of cardiomyocytes to different inotropic agents suggesting that a common final step of the inotropic cascade might be altered by TNFα. Though energy metabolism of TNFα exposed cells was affected also, reduction of high energy phosphate levels alone did not explain the observed inhibition of the inotropic response of the cardiomyocytes.

Key words

TNF cardiomyocytes inotropic response high energy phosphates 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    De Meules JE, Pigula FA, Mueller M, Raymond SJ, Gamelli RL: Tumor necrosis factor and cardiac function. J Trauma 32: 686–692, 1992Google Scholar
  2. 2.
    Geng Y, Hansson GK, Holme E: Interferon-γ and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circ Res 71: 1268–1276, 1992Google Scholar
  3. 3.
    Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF: Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad 86: 6753–6757, 1989Google Scholar
  4. 4.
    Gulick T, Pieper SJ, Murphy MA, Lange LG, Schreiner GF: A new method for assessment of cultured cardiac myocyte contractility detects immune factor-mediated inhibition of β-adrenergic responses. Circulation 84: 313–321, 1991Google Scholar
  5. 5.
    Reithmann C, Gierschik P, Werdan K, Jacobs KH: Tumor necrosis factor up-regulates Giα and Gβ proteins and adenylyl cyclase responsiveness in rat cardiomyocytes. Europ J Pharmacol 206: 53–60, 1991Google Scholar
  6. 6.
    Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL: Tumor necrosis factor and cardiac function. Science 257: 387–389, 1992Google Scholar
  7. 7.
    Tredget EE, Yu Ym, Zhong S, Burini R Okusawa S, Gelfand JA, Dinarello CA, Young VR, Burke JF: Role of interleukin- 1 and tumor necrosis factor on energy metabolism in rabbits. Am J Physiol 255: E760-E768, 1988Google Scholar
  8. 8.
    Finkel MS, Hoffman RA, Shen L, Oddis CV, Simmons RL, Hattler BG: Interleukin-6 (IL-6) as mediator of stunned myocardium. Am J Cardiol 71: 1231–1232, 1993Google Scholar
  9. 9.
    Hollenberg SM, Cunnion RE, Lawrence M, Kelly JL, Parillo JE: Tumor necrosis factor depresses myocardial cell function: Results using an in vitro assay of myocyte performance. Clin Res 37: 528A, 1989Google Scholar
  10. 10.
    Kumar A, Dimon C, Snell RJ, Hollenberg SM, Cunnion R, Lawrence M, Uretz E, Parrillo JE: Tumor necrosis factor produces depression of myocardial cell contraction in vitro (abstr). Crit Care Med 20: 278, 1993Google Scholar
  11. 11.
    Vincent JL, Bakker J, Marecaux G, Schandene L, Kahn RJ, Dupon E: Administration of Anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study. Chest 101: 810–815, 1992Google Scholar
  12. 12.
    Boekstegers P, Weidenhofer S, Zell R, Pilz G, Holler E, Ertl W, Kapsner T, Redl H, Schlag G, Kaul M, Kempeni J, Stenzel R Werdan K: Repeated administration of a F(ab′)2 fragment of an anti-tumor necrosis factor a monoclonal antibody in patients with severe sepsis: Effects on the cardiovascular system and cytokine levels. Shock 1: 237–245, 1994Google Scholar
  13. 13.
    Lanore JJ, Dhainaut JF, Fisher JC, Opal SM, Zimmerman J, Nightingale P, Stephens S, Schein RI, Panacek EA, Vincent JL, Foulke GE, Warren EL, Gerrard C, Park G, Bodmer MW, Cohen J, Van der Linden C, Sadoff JC, Pochard F and the CB0006 Study Group: Effects of an anti-TNF IgG monoclonal antibody on left ventricular performance in septic patients. Intens Care Med 18: 49 (abstr), 1992Google Scholar
  14. 14.
    Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failiure. N Engl J Med 323: 236–241, 1990Google Scholar
  15. 15.
    Maury CPJ, Teppo AM: Circulating tumour necrosis factor-α (cachectin) in myocardial infarction. Int Med 225: 333–336, 1989Google Scholar
  16. 16.
    Latini R, Bianchi M, Correale E, Dinarello CA, Fanzuzzi G, Fresco C, Maggioni AP, Mengozzi M, Romano S, Shapiro L, Sironi M, Tognoni G, Turato R, Ghezzi P: Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. Cardiovasc Pharmacol 23: 1–6, 1994Google Scholar
  17. 17.
    Fisher CJ, Opal SM, Dhainaut JF, Stephens S, Zimmermann JL, Nightingale P, Harris SJ, Schein RM, Panacek EA, Vincent JL, Foulke GE, Warren EL, Gerrard C, Park G, Bodmer MW, Cohen J, Van der Linden C, Gross AL, SadoffJC and the CB0006 sepsis syndrome study group: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 21: 318–327, 1993Google Scholar
  18. 18.
    Weisensee D, Bereiter-Hahn J, Schoeppe W, Low-Friedrich J: Effects of cytokines on the contractility of cultured cardiac myocytes. Int J lmmunopharmac 15: 581–587, 1993Google Scholar
  19. 19.
    Mela-Riker L, Bartos D, Viessis AA, Widener L, Muller P, Trunkey DD: Chronic hyperdynamic sepsis in the rat. 11. Characterization of liver and muscle energy metabolism. Circ Shock 36: 83–92, 1992Google Scholar
  20. 20.
    Möller A, Emling F, Blohm D, Schlick E, Schollmeier K: Monoclonal antibodies to human tumor necrosis factor α: in vitro and in vivo application. Cytokine 2: 162–169, 1990Google Scholar
  21. 21.
    Werdan K, Erdmann E: Preparation and culture of embryonic and neonatal heart muscle cells: Modification of transport activity. Meth Enzymol 173: 634–662, 1989Google Scholar
  22. 22.
    Boekstegers P, Pfeiffer A, Peter W, Werdan K: Contractile dysfunction of ‘reperfused’ neonatal rat heart cells: a model for studying ‘myocardial stunning’ at the cellular level? Adv Exp Med Biol 317: 573–582, 1992Google Scholar
  23. 23.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenolreagent. J Biol Chem 193: 265–270, 1951Google Scholar
  24. 24.
    Furst W, Hallström S: Simultaneous determination of myocardial nucleosides, purine bases and creatine phosphate by ion-pair high performance liquid chromatography. Chromatography 578: 39–44, 1992Google Scholar
  25. 25.
    Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest 93: 2303–2312, 1993Google Scholar
  26. 26.
    Schulze-Osthoff K, Bakker AC, Vanhaesebrook B, Beyaert R, Jacob WA, Fiers W: Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Biol Chem 267: 5317–5323, 1992Google Scholar
  27. 27.
    Galloway CJ, Madanat MS, Mitra G. Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity. Immunol Meth 140: 37–43, 1991Google Scholar
  28. 28.
    Lancaster JR, Laster SM, Gooding LR: Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor. FEBS 248: 169–174, 1989Google Scholar
  29. 29.
    Eizirik DL: Interleukin-1 induces impairment in pancreatic islet oxidative metabolism of glucose is potentiated by tumor necrosis factor. Acta Endocrin 119: 321–325, 1988Google Scholar
  30. 30.
    Burns AH, Giaimo ME, Summer WR: Dichloroacetic acid improves in vitro myocardial function following in vivo endotoxin administration. J Crit Care 1: 11–17, 1986Google Scholar
  31. 31.
    Hotchkiss RS, Song SK, Neil JJ, Chen RD, Manchester JK, Karl IE, Lowry OH, Ackerman JJ: Sepsis does not impair tricarboxylic acid cycle in the heart. Am J Physiol 260: C50-C57, 1991Google Scholar
  32. 32.
    McDonough KH, Henry JJ, Lang CH, Spitzer JJ: Substrate utilization and high energy phosphate levels of hearts from hyperdynamic septic rats. Cire Shock 18: 161–170, 1986Google Scholar
  33. 33.
    Laughlin MH, Smyk-Randall EM, Novotny MJ, Brown OR, Adams HR: Coronary blood flow and cardiac adenine nucleotides in E. coli endotoxemia in dogs: effects of oxygen radical scavengers. Circ Shock 25: 173–185, 1988Google Scholar
  34. 34.
    Mori E, Hasebe M, Kobayashi K, Lijima N: Alterations in metabolite levels in carbohydrate and energy metabolism of rat in hemorrhagic shock and sepsis. Metabolism 36: 14–20, 1987Google Scholar
  35. 35.
    Wagenknecht B, Beuttler C: Alterations of β-receptor-adenylyl cyclase coupling by long term ATP depletion in cultured rat cardiomyocytes. Europ J Pharmacol 208: 261–264, 1991Google Scholar
  36. 36.
    Kramer SM, Aggarwal BB, Eessalu TE, McCabe SM, Ferraiolo BL, Figari IS, Palladino MA: Characterization of the in vitro and in vivo species preference of human and rnurine tumor necrosis factor-α. Cancer Res 48: 920–925, 1988Google Scholar
  37. 37.
    v.Tits LJR, Bemelmans MHA, Steinshamm S, Waage A, Leeuwenberg JFM, Buurman WA: Non-signaling functions of TNF-R75: Findings in man and mouse. Circ Shock 44: 40–44, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Peter Boekstegers
    • 1
  • Iris Kainz
    • 1
  • Wolfgang Giehrl
    • 1
  • Wolfgang Peter
    • 1
  • Karl Werdan
    • 1
  1. 1.Department of Internal Medicine I, Klinikum GrofßhadernUniversity of MunichGermany

Personalised recommendations